ViruBac ApS: Financial statements 2023
CVR: 41362731
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
ViruBac ApS (CVR 41362731) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -14,804 and a net result of DKK 77,143 compared with DKK -24,025 the year before. Equity in the 2023 report amounted to DKK 1,894. The solvency ratio was 2.8%.
- Gross Profit
- DKK -14,804
- Profit/Loss
- DKK 77,143
- Equity
- DKK 1,894
- Total Assets
- DKK 66,676
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -15 t. | 77 t. | 2 t. | - |
| 2022 | - | -19 t. | -24 t. | -75 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of October 9, 2023, Kaspar Haustrup Hermansen has stepped down as director of ViruBac ApS.
ViruBac ApS was dissolved on October 9, 2023.
About ViruBac ApS
ViruBac ApS was a Danish company of the type Anpartsselskab based in Faaborg, founded in 2020. The company has been dissolved on 9 October 2023. The company was registered under the industry Fremstilling af farmaceutiske råvarer. In 2023, the company reported a gross profit of DKK -14,804 and a net result of DKK 77,143 compared with DKK -24,025 the year before. Equity in the 2023 report amounted to DKK 1,894.